CTLA4-Ig (Abatacept) for Prevention of Type 1 Diabetes in Relatives At-Risk

This study is for:

About this study

Abatacept is used to treat rheumatoid arthritis and other autoimmune diseases. In 2011, the TrialNet consortium showed that it preserved pancreas function in people with recently-diagnosed T1D (link to Lancet 2011; 378: 412–19). We are now testing whether Abatacept also preserves pancreas function earlier in the course of T1D.

This is a randomised controlled trial, meaning one half of the participants are randomly allocated to receive Abatacept and the other half to placebo (dummy treatment). Participation involves 13 monthly infusions at a research unit followed by 6-monthly follow-up visits.

 

This trial is running in Adelaide and Melbourne.

For more information about this study